Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.4 CAD | 0.00% | +4.27% | +4.73% |
03-29 | Big Pharma Split Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Big Pharma Split Corp. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Business Summary
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Investment and Related Activities
100.0
%
| 4 | 100.0 % | 3 | 100.0 % | -20.03% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 4 | 100.0 % | 3 | 100.0 % | -20.03% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Kovacs
CEO | Chief Executive Officer | - | - |
Daniel Lazzer
DFI | Director of Finance/CFO | - | - |
Mary Medeiros
COO | Chief Operating Officer | - | - |
David Balsdon
CMP | Compliance Officer | - | - |
Chief Investment Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Kovacs
CEO | Chief Executive Officer | - | - |
Mary Medeiros
COO | Chief Operating Officer | - | - |
Nicholas Bontis
BRD | Director/Board Member | - | - |
Company contact information
Big Pharma Split Corp.
610 Chartwell Road Suite 204
L6J 4A5, Oakville
+416-649-4541
http://www.harvestportfolios.com/closed-end-funds/big-pharma-split-corp/1st Jan change | Capi. | |
---|---|---|
+4.73% | 12.31M | |
+2.11% | 491M | |
+7.00% | 242M | |
+38.10% | 231M | |
+21.29% | 196M | |
+11.85% | 116M | |
+1.77% | 85.81M | |
-13.17% | 52.17M |
- Stock Market
- Equities
- PRM Stock
- Company Big Pharma Split Corp.